ID   NUGC-3/5-FU/L
AC   CVCL_L502
SY   NUGC-3/5FU/L; NUGC-3/5-FU; NUGC-3/5FU
DR   cancercelllines; CVCL_L502
DR   Wikidata; Q54931162
RX   PubMed=8609072;
RX   PubMed=10359051;
RX   PubMed=15767549;
CC   Part of: JFCR45 cancer cell line panel.
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Brachialis muscle; UBERON=UBERON_0001506.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1612 ! NUGC-3
SX   Male
AG   72Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 17
//
RX   PubMed=8609072; DOI=10.1111/j.1349-7006.1996.tb03161.x;
RA   Inaba M., Mitsuhashi J., Sawada H., Miike N., Naoe Y., Daimon A.,
RA   Koizumi K., Tsujimoto H., Fukushima M.;
RT   "Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant
RT   human stomach cancer cells.";
RL   Jpn. J. Cancer Res. 87:212-220(1996).
//
RX   PubMed=10359051; DOI=10.1111/j.1349-7006.1999.tb00754.x;
RA   Inaba M., Sawada H., Sadata A., Hamada H.;
RT   "Circumvention of 5-fluorouracil resistance in human stomach cancer
RT   cells by uracil phosphoribosyltransferase gene transduction.";
RL   Jpn. J. Cancer Res. 90:349-354(1999).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//